HemoCue Introduces a Point-of-Care Urine Albumin System for Microalbuminuria Screening
Posted on: Monday, 25 July 2005, 21:01 CDT
LAKE FOREST, Calif., July 25 /PRNewswire/ -- HemoCue today introduced a point-of-care system for the quantitative determination of microalbuminuria. This is an ideal system for health care professionals who care for diabetes patients to screen for early signs of kidney failure.
Microalbuminuria is a powerful predictor for the future development of diabetic nephropathy and cardiovascular disease. Diabetic nephropathy (kidney failure) is one of the most serious and the most expensive complications of diabetes. Microalbuminuria is the first clinical evidence of renal dysfunction and an indication of disease progression. The American Diabetes Association (ADA) recommends annual microalbuminuria screening for individuals with type 1 diabetes after 5 years from disease duration. Annual microalbuminuria screening for individuals with type 2 diabetes is recommended from the time of diagnosis.
The system consists of a portable analyzer and disposable cuvettes containing freeze-dried reagents with anti-human albumin antibodies. The sample is drawn into the cuvette by capillary action, placed in the analyzer, and mixed through vibration. The immunochemical reaction is completed within 90 seconds. The measuring range is 10-150 mg/L and the analyzer requires 15 microliters of a spot or timed urine collection.
The HemoCue Urine Albumin system has superior precision and accuracy because the analyzers are factory calibrated and the cuvettes have no clinically significant lot-to-lot variation. The system has received high recommendations from international experts in renal medicine. The HemoCue Urine Albumin system performs quantitative microalbuminuria testing at the point-of-care.
About HemoCue
HemoCue develops, produces, and markets medical products for point-of-care testing. The company's annual sales exceed $50 million and its products are distributed in more than 100 countries worldwide. The fundamental concept behind HemoCue products is the ability to perform common blood and urine tests at the point of care without sacrificing the accuracy and precision offered by a central clinical lab.
HemoCue is owned by EQT. EQT is a leading private equity group in Northern Europe.
For additional information about HemoCue or its products and services, visit http://www.hemocue.com/.
HemoCue, Inc.
CONTACT: Lily Sunkin, National Marketing Manager of HemoCue, Inc.,+1-949-859-2630, lily@hemocue.com
Web site: http://www.hemocue.com/
Source: PRNewswire
Related Articles
- Quest Diagnostics to Support Walgreens and Take Care Health Systems' Offer of Free Health Services by Providing Certain Free Laboratory Testing
- Take Care Health Systems Expands Vaccine Program
- Take Care Health Systems and Walgreens Open Four New Health Corner Clinics in Chicago Area and Kick Off National Influenza Vaccination Week From Nov. 27 to Dec. 3
- Carondelet Health Network Selects Patient Care Technology Systems' Automatic Tracking Software; Software Will Track Patients and Mobile Medical Equipment in Emergency Department and Operating Rooms
- Patient Care Technology Systems Appoints Vice President Of Technology
- Viant Group Advises Take Care Health Systems on $77 Million Private Equity Financing
- Ethidium Health Systems Powers Medical Record Network for Take Care Health Systems
- Rite Aid Partners With Take Care Health Systems(SM) To Offer In-Store Nurse Practitioner Health Care Services
- Research and Markets: Diabetes, Metabolic Syndrome & Cardiovascular Disease: Reshaping Tomorrow's Diabetes Market
- Research and Markets: Business Opportunities in Diabetes, Obesity and Metabolic Disease Market Analysed
 |
 |
User Comments (0)
RSS Feeds